Literature DB >> 10566633

Impaired cardiac performance in elderly patients with growth hormone deficiency.

A Colao1, A Cuocolo, C Di Somma, G Cerbone, A M Della Morte, E Nicolai, R Lucci, M Salvatore, G Lombardi.   

Abstract

Several evidences indicate that GH and/or insulin-like growth factor I (IGF-I) are involved in the regulation of cardiovascular function. In patients with childhood and adulthood-onset GH deficiency (GHD), the impairment of cardiac performance is manifest primarily as a reduction in the left ventricular (LV) mass (LVM), inadequacy of LV ejection fraction both at rest and at peak exercise, and abnormalities of LV diastolic filling. No study has been reported to date in elderly GHD patients that investigated cardiac function. In particular, it is unknown whether cardiac function is modified in accordance with patients' age as a physiological response to aging, as in normal subjects the rate and extent of LV filling are reduced with age. This study was designed to evaluate heart morphology and function, by echocardiography and equilibrium radionuclide angiography, respectively, in rigorously selected elderly patients with GHD but without evidence of other complications able to affect cardiac performance. Eleven patients with hypopituitarism (6 men and 5 women, aged 60-72 yr) and 11 sex- age- and body mass index-matched healthy subjects entered this study. None of the patients and controls presented with or had previously suffered from other concomitant diseases, such as diabetes mellitus, coronary artery diseases, long-standing hypertension, and hyperthyroidism, which could affect cardiac function. All patients had been previously operated on via the transsphenoidal and/or transcranic route for nonfunctioning pituitary adenoma, meningioma, or craniopharyngioma, and 6 of them had been irradiated. Eight patients had FSH/LH insufficiency, 5 had TSH insufficiency, and 6 had ACTH insufficiency, appropriately replaced. All subjects were tested with the combined arginine plus GHRH test showing a GH response below 9 microg/L. No significant difference was found in plasma IGF-I levels (49.2 +/- 8.5 vs. 71.8 +/- 7.5 microg/L) between patients and controls. However, IGF-I levels were lower than the normal range in 8 patients and 3 controls. Interventricular septum thickness (9.1 +/- 0.2 vs. 9.1 +/- 0.2 mm), LV posterior wall thickness (9.1 +/- 0.2 vs. 9.0 +/- 0.2 mm), and LVM after correction for body surface area (97.6 +/- 1.8 vs. 99.9 +/- 1.5 g/m2) were similar in patients and controls. Similarly, the LV ejection fraction at rest was similar in patients and controls (57.1 +/- 2% vs. 63.2 +/- 2.5%; P = NS), and it was normal (> or = 50%) in all controls and in 10 of 11 patients. By contrast, the LV ejection fraction at peak exercise was markedly depressed in elderly GHD patients compared to age-matched controls (51 +/- 2.5% vs. 73.3 +/- 3%; P < 0.001). A normal response (> or = 5% increase compared to basal value) of LV ejection fraction at peak exercise was found in 8 controls (72.7%) and in 2 of 11 patients (18.2%). No difference was found in the peak rate of LV filling, whether peak filling rate was normalized to end-diastolic volume (2.5 +/- 0.2 vs. 2.6 +/- 0.2 end-diastolic volume/s) or stroke volume (4.3 +/- 0.3 vs. 4.0 +/- 0.3 stroke volume/s), between patients and controls. Finally, exercise duration was significantly shorter in elderly GHD patients than in age-matched controls (7.2 +/- 2.1 vs. 9.1 +/- 0.2 min; P < 0.01). In the patient group, the GH peak after arginine plus GHRH test was significantly correlated with the LV ejection fraction at rest (r = 0.822; P < 0.01), whereas IGF-I was significantly correlated with the peak rate of LV filling whether the peak filling rate was normalized to end-diastolic volume (r = -0.863; P < 0.001) or stroke volume (r = -0.616; P < 0.05) or expressed as the ratio of peak filling rate to peak ejection fraction rate (r = -0.736; P < 0.01). Disease duration was significantly correlated with heart rate at peak exercise (r = 0.614; P < 0.05) and with systolic and diastolic blood pressures both at rest (r = 0.745; P < 0.01 and r = 0.650; P < 0.05) and at peak exercise (r = 0.684; P < 0.05 and r =

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566633     DOI: 10.1210/jcem.84.11.6112

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Recombinant human GHRH(1-44)NH2: clinical utility and therapeutic development program.

Authors:  M R Ehlers
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study.

Authors:  V Gasco; L Roncoroni; M Zavattaro; C Bona; A Berton; E Ghigo; M Maccario; S Grottoli
Journal:  J Endocrinol Invest       Date:  2019-08-22       Impact factor: 4.256

Review 4.  The cardiovascular system in growth hormone excess and growth hormone deficiency.

Authors:  G Lombardi; C Di Somma; L F S Grasso; M C Savanelli; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2012-11-12       Impact factor: 4.256

5.  The effect of growth hormone replacement therapy on the morphological and functional changes in the left ventricle in patients with adult-onset growth hormone deficiency.

Authors:  Anton Dlesk; Gabriel Kamenský; Ivica Lazúrová; Martin Kužma; Juraj Payer
Journal:  Wien Klin Wochenschr       Date:  2014-07-01       Impact factor: 1.704

Review 6.  Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.

Authors:  E Ghigo; G Aimaretti; E Arvat; F Camanni
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

7.  Role of Growth Hormone Deficiency and Treatment in Chronic Kidney Disease.

Authors:  Diptesh Gupta; Michael Gardner; Adam Whaley-Connell
Journal:  Cardiorenal Med       Date:  2011-07-26       Impact factor: 2.041

8.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

9.  Effects of short-term treadmill exercise training or growth hormone supplementation on diastolic function and exercise tolerance in old rats.

Authors:  Leanne Groban; Harrison Jobe; Marina Lin; Timothy Houle; Dalane A Kitzman; William Sonntag
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2008-09       Impact factor: 6.053

10.  A comparison of the growth responses following intramuscular GHRH plasmid administration versus daily growth hormone injections in young pigs.

Authors:  Amir S Khan; Ruxandra Draghia-Akli; Roman J Shypailo; Kenneth I Ellis; Harry Mersmann; Marta L Fiorotto
Journal:  Mol Ther       Date:  2009-10-06       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.